Jim Plante

IIVIVAs team develops living therapeutics to cure patients with kidney failure. End-stage kidney disease affects over 500,000 patients in the United States and despite transplant being the only definitive treatment for ESKD, most will never receive a donor kidney. We use emerging complimentary technologies in tissue engineering, 3D additive manufacturing, and stem cell biology to realize the potential of regenerative medicine to end donor organ shortage. We develop biomimetic platforms and systems not only to provide therapies but to serve as the foundational building blocks for the next generation of advanced organ therapeutics.

We’ve moved! Follow @Omnitracs for the latest on the #transportation #SaaS industry. Your one-stop shop for all things #safety, #compliance, #routing, #dispatch and more.

The Leader in Wireless Networking and Ultra-Low Latency. E-Band Communications designs ultra-low latency multi-gigabit capacity wireless technologies and solutions for algorithmic and high-frequency trading clients in financial services. We pioneered highest capacity mmWave technology for public and corporate wireless networks. Thousands of leading Carriers, Businesses and Government Agencies use E-Bands 60, 70 and 80 GHz solutions in applications such as LTE, 5G, mobile backhaul, fiber extension, military and private networks.

IMX Data offers comprehensive coverage of over 85 billion medical, pharmacy, and hospital claims, delivering unparalleled clarity into the healthcare landscape.

IMX Health, LLC was founded to bring price discovery, risk transference tools, and data solutions to the American healthcare sector. We are dedicated to establishing a marketplace for tradable healthcare products where participants can effectively manage risk and capitalize on previously unforeseen opportunities. We aim to create a more transparent and efficient healthcare industry that will ultimately result in a more dynamic healthcare sector.

IIVIVAs team develops living therapeutics to cure patients with kidney failure. End-stage kidney disease affects over 500,000 patients in the United States and despite transplant being the only definitive treatment for ESKD, most will never receive a donor kidney. We use emerging complimentary technologies in tissue engineering, 3D additive manufacturing, and stem cell biology to realize the potential of regenerative medicine to end donor organ shortage. We develop biomimetic platforms and systems not only to provide therapies but to serve as the foundational building blocks for the next generation of advanced organ therapeutics.

Helping people live well longer. Klotho Therapeutics, Inc., (KTI) is a privately held biotechnology company developing modified recombinant versions of the human protein Klotho that has shown great potential to delay diseases of aging and improve longevity. Klotho Team has 250+ Years Pharma Experience, 500+ Clinical Trials, including 60+ drug Approvals including numerous Blockbuster Drugs The company builds upon the $200+ million previously invested in Klotho research that demonstrates how Klotho, a naturally occurring protein in humans and animals, can positively impact aging, cognition, kidney function, fibrosis, and cancer. KTI has worldwide patents on Klotho proteins. KTI is well positioned to enter human trials within 12 months focused on its first indication: to slow the progression of kidney failure, which affects up to 40 million patients in the US per year, with over 600,000 currently on dialysis. Kidney disease represents a multi-billion-dollar market opportunity in the U.S. alone.

The Foundation for Kidney Transplant Research was founded by Jim Plante, a biotechnology entreprenuer and investor (Thynk Capital, Pathway Genomics, Klotho Therapeutics) after learning he and his siblings carried the genetic mutation for polycystic kidney disease (PKD). PKD patients normally require a kidney transplant at some point in their lives.. Typically, PKD carriers require a kidney transplant at some point in their lives. The best outcomes are usually achieved when the donor is a family member. With the knowledge that he and his family would need a kidney from a non-related donor, Plante began to immerse himself in learning about the transplant process. It quickly became apparent to Plante that the transplant process is broken – thousands of kidney patients die every year waiting for an organ, the black market in kidneys is active across the globe and the cost of patients waiting on dialysis is one of the biggest in Medicare. Plante also learned about the disincentives to donating that living donors face. Organ transplantation in America is governed by the National Organ Transplant Act (NOTA) of 1984, a law passed at a time when kidney disease was less prevalent and far fewer Americans needed a kidney transplant. NOTA prohibits “valuable consideration” for organs. Under NOTA, kidney donors find themselves paying for travel associated with their donation, weeks of lost wages during recovery time, follow up medical visits and the like. Plante established the Foundation for Kidney Transplant Research to explore policy options to find a solution to immediately increase the number of kidneys available for transplant, educate the public on the problem and to quantify public support for various policy approaches.